Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is Ally Bridge Group NY LLC’s 6th Largest Position

Ally Bridge Group NY LLC lessened its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,000 shares of the biotechnology company’s stock after selling 1,500 shares during the period. Sarepta Therapeutics accounts for approximately 4.8% of Ally Bridge Group NY LLC’s portfolio, making the stock its 6th largest position. Ally Bridge Group NY LLC owned approximately 0.08% of Sarepta Therapeutics worth $8,992,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in SRPT. Blueshift Asset Management LLC acquired a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at about $262,000. Finepoint Capital LP lifted its stake in Sarepta Therapeutics by 0.5% in the third quarter. Finepoint Capital LP now owns 133,535 shares of the biotechnology company’s stock valued at $16,677,000 after buying an additional 700 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $237,000. Qsemble Capital Management LP purchased a new position in shares of Sarepta Therapeutics during the third quarter worth approximately $311,000. Finally, Fisher Asset Management LLC increased its holdings in shares of Sarepta Therapeutics by 1.3% in the 3rd quarter. Fisher Asset Management LLC now owns 18,155 shares of the biotechnology company’s stock valued at $2,267,000 after acquiring an additional 239 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 14.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 7.70% of the company’s stock.

Wall Street Analysts Forecast Growth

SRPT has been the topic of several research reports. Robert W. Baird lowered their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Barclays reduced their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Jefferies Financial Group started coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 target price on the stock. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Needham & Company LLC lowered their price objective on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $175.77.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $137.94 on Thursday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm’s 50-day simple moving average is $121.90 and its 200 day simple moving average is $131.39. Sarepta Therapeutics, Inc. has a 52 week low of $78.67 and a 52 week high of $173.25. The firm has a market capitalization of $13.18 billion, a PE ratio of 110.35 and a beta of 0.81.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.